BioCentury

7:00 AM GMT, Jun 18, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc.'s relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway could delay the time to when the disease becomes hormone refractory.

Prostate cancer therapies have predominantly targeted the androgen pathway, as aberrant androgen production drives tumor growth and metastases. These treatments include older therapies such as androgen hormone antagonists and newer compounds such as Zytiga abiraterone from Johnson & Johnson, which

Read the full 845 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.